pharmacogenomics
Genedrive Point-of-Care PGx Test for Stroke Patients Nabs UKCA Mark
The test can determine which stroke patients may respond to clopidogrel treatment in about one hour.
Genedrive, U of Manchester Collaborate to Further Validate CYP2C19 Test
Genedrive's CYP2C19 ID Kit will be evaluated by multiple stakeholders in a program funded by Innovate UK and the UK Innovation Accelerator.
UK's NICE Recommends Genetic Testing for Therapy Selection in Stroke Patients
Clopidogrel is less effective at preventing subsequent strokes in patients with certain variations in the CYP2C19 gene and testing could aid treatment selection.
Castle Biosciences Q4 Revenues Jump 53 Percent as Firm Beats Analyst Expectations
Castle also reported full-year revenues at the top end of previously issued guidance and offered full-year 2023 guidance ahead of Wall Street expectations.
NewStem, MSK Innovation Hub Team to Validate Cancer Diagnostics Software Platform
The Israeli startup called this collaboration a necessary step toward commercializing its CE-marked NewStem Software Diagnostic Device for reducing oncology drug resistance.
Oct 17, 2022
Sep 26, 2022
UK's NICE to Accelerate Assessment of Genedrive Test
May 31, 2022
Nalagenetics Gets CE Mark for PGx Software Module
Apr 13, 2022
Apr 5, 2022
Castle Biosciences to Acquire AltheaDx for $65M
Mar 25, 2022
Nalagenetics Closes $12.6M Series A Funding Round
Feb 28, 2022
May 26, 2021